Literature DB >> 20153594

Identification, isolation and characterization of new impurity in rabeprazole sodium.

P Sreenivasa Rao1, Uttam Kumar Ray, P Badarinadh Gupta, D V N Srinivasa Rao, Aminul Islam, Pradeep Rajput, K Mukkanti.   

Abstract

Rabeprazole sodium [1] is a proton pump inhibitor, used as an antiulcerative. During the manufacturing of rabeprazole sodium, we observed an unknown impurity at levels 0.05-0.1% in HPLC analysis along with the known potential impurities. This new unknown impurity was isolated using preparative liquid chromatography. Based on the complete spectral analysis ((1)H NMR, (13)C NMR, DEPT, Mass and IR), this new impurity was designated as 2-[[(3-methyl-4-(methylthio)-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole (methylthio impurity of rabeprazole). Impurity isolation, structure elucidation and probable formation mechanism was discussed. Copyright (c) 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20153594     DOI: 10.1016/j.jpba.2010.01.034

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  3 in total

1.  New benzimidazole acridine derivative induces human colon cancer cell apoptosis in vitro via the ROS-JNK signaling pathway.

Authors:  Kang Chen; Bi-zhu Chu; Feng Liu; Bin Li; Chun-mei Gao; Lu-lu Li; Qin-sheng Sun; Zhi-fa Shen; Yu-yang Jiang
Journal:  Acta Pharmacol Sin       Date:  2015-08-03       Impact factor: 6.150

2.  Oxibendazole inhibits prostate cancer cell growth.

Authors:  Qiaoli Chen; Yuhua Li; Xiaoyu Zhou; Runsheng Li
Journal:  Oncol Lett       Date:  2017-12-11       Impact factor: 2.967

3.  Development and Validation of a Stability-Indicating RP-HPLC Method for the Determination of Process-Related Impurities and Degradation Products of Rabeprazole Sodium in Pharmaceutical Formulation.

Authors:  Navneet Kumar; Dhanaraj Sangeetha
Journal:  Sci Pharm       Date:  2013-03-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.